33787-05-2

Basic information

• Product Name: DL-2,6-DIFLUOROPHENYLALANINE
• Synonyms: 2,6-DIFLUOROPHENYLALANINE;2,6-DIFLUORO-DL-PHENYLALANINE;2,6-DIFLUORO-L-PHENYLALANINE;2-AMINO-3-(2,6-DIFLUORO-PHENYL)-PROPIONIC ACID;L-2,6-DIFLUOROPHENYL-ALANINE;DL-2,6-DIFLUOROPHENYLALANINE;H-2,6-DIFLUORO-PHE-OH HCL;(S)-2-AMINO-3-(2,6-DIFLUORO-PHENYL)-PROPIONIC ACID
• CAS NO: 33787-05-2
• Molecular Formula: C₉H₉F₂NO₂
• Molecular Weight: 201.17
• Product Categories: Amino Acid Derivatives
• Mol File: 33787-05-2.mol
• Article Data: 9

Chemical Properties

• Melting Point: 256 °C
• Boiling Point: 301.1°Cat760mmHg
• Flash Point: 135.9°C
• Appearance: /
• Density: 1.379g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.20±0.10(Predicted)
• CAS DataBase Reference: DL-2,6-DIFLUOROPHENYLALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: DL-2,6-DIFLUOROPHENYLALANINE(33787-05-2)
• EPA Substance Registry System: DL-2,6-DIFLUOROPHENYLALANINE(33787-05-2)

Safety Data

• Hazardous Substances Data: 33787-05-2(Hazardous Substances Data)

Usage

Uses

L-2,6-Difluorophenylalanine

Upstream product

• 266360-50-3 2-acetylamino-3-(2,6-difluoro-phenyl)-propionic acid 
• 152152-09-5 (E)-2,6-difluorocinnamic acid 
• 85118-00-9 2,6-Difluorobenzyl bromide 
• 266360-45-6 diethyl α-acetamido, α-(2,6-difluorobenzyl)malonate 
• 627910-22-9 (2S)-2-benzyloxycarbonylamino-3-(2,6-difluorophenyl)propionic acid 
• 710350-50-8 (3S,5S,6R)-3-(2,6-difluorophenylmethyl)-5,6-diphenyl-2,3,5,6-tetrahydro-4H-1,4-oxazine-2-one 

Downstream Products

• 167993-07-9 N-{[(1,1-dimethylethyl)oxy]carbonyl}-2,6-difluoro-L-phenylalanine 
• 1235020-13-9 N-{[(9H-fluoren-9-yl)methoxy]carbonyl}-2,6-difluoro-L-phenylalanine 

Relevant articles and documents

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS

The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceu